Cipla Ltd
NSE:CIPLA

Watchlist Manager
Cipla Ltd Logo
Cipla Ltd
NSE:CIPLA
Watchlist
Price: 1 473.2 INR 0.39% Market Closed
Market Cap: 1.2T INR

EV/EBIT
Enterprise Value to EBIT

18
Current
20.8
Median
16.3
Industry
Lower than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
18
=
Enterprise Value
1.1T INR
/
EBIT
60.2B INR
Market Cap EV/EBIT
IN
Cipla Ltd
NSE:CIPLA
1.2T INR 18
US
Eli Lilly and Co
NYSE:LLY
711.5B USD 37.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 17 702.3
US
Johnson & Johnson
NYSE:JNJ
371.5B USD 16.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK 15.7
CH
Roche Holding AG
SIX:ROG
209.8B CHF 11.1
CH
Novartis AG
SIX:NOVN
186.7B CHF 13.9
UK
AstraZeneca PLC
LSE:AZN
164.9B GBP 197.1
US
Merck & Co Inc
NYSE:MRK
194.1B USD 10.1
IE
Endo International PLC
LSE:0Y5F
163.5B USD 655.3
US
Pfizer Inc
NYSE:PFE
132.7B USD 10.3
EBIT Growth EV/EBIT to Growth
IN
Cipla Ltd
NSE:CIPLA
Average EV/EBIT: 1 698.9
18
6%
3
US
Eli Lilly and Co
NYSE:LLY
37.7
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.3
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
15.7
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.1
6%
1.9
CH
Novartis AG
SIX:NOVN
13.9
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.1
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.1
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
10%
1

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
17.2
2-Years Forward
EV/EBIT
16.9
3-Years Forward
EV/EBIT
15.2